A detailed history of Morgan Stanley transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,256,445 shares of SAGE stock, worth $13.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,256,445
Previous 870,564 44.33%
Holding current value
$13.6 Million
Previous $18.9 Million 24.81%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$18.62 - $26.95 $7.19 Million - $10.4 Million
385,881 Added 44.33%
1,256,445 $23.5 Million
Q4 2023

Feb 13, 2024

BUY
$17.1 - $22.26 $113,407 - $147,628
6,632 Added 0.77%
870,564 $18.9 Million
Q3 2023

Nov 15, 2023

BUY
$16.75 - $48.98 $8.58 Million - $25.1 Million
512,021 Added 145.5%
863,932 $17.8 Million
Q2 2023

Aug 14, 2023

SELL
$40.65 - $59.54 $843,121 - $1.23 Million
-20,741 Reduced 5.57%
351,911 $16.5 Million
Q1 2023

May 15, 2023

SELL
$37.27 - $46.57 $4.88 Million - $6.1 Million
-130,983 Reduced 26.01%
372,652 $15.6 Million
Q4 2022

Feb 14, 2023

BUY
$32.2 - $43.61 $5.25 Million - $7.1 Million
162,920 Added 47.82%
503,635 $19.2 Million
Q3 2022

Nov 14, 2022

SELL
$32.28 - $43.27 $7.51 Million - $10.1 Million
-232,585 Reduced 40.57%
340,715 $13.3 Million
Q2 2022

Oct 27, 2022

BUY
$27.52 - $37.99 $225,058 - $310,682
8,178 Added 1.45%
573,300 $18.5 Million
Q2 2022

Aug 15, 2022

BUY
$27.52 - $37.99 $225,058 - $310,682
8,178 Added 1.45%
573,300 $18.5 Million
Q1 2022

Oct 27, 2022

SELL
$30.71 - $45.71 $251,146 - $373,816
-8,178 Reduced 1.43%
565,122 $18.7 Million
Q1 2022

May 13, 2022

BUY
$30.71 - $45.71 $8.49 Million - $12.6 Million
276,594 Added 95.86%
565,122 $18.7 Million
Q4 2021

Feb 14, 2022

SELL
$37.06 - $47.11 $1.72 Million - $2.18 Million
-46,312 Reduced 13.83%
288,528 $12.3 Million
Q3 2021

Nov 15, 2021

BUY
$40.26 - $57.37 $13.5 Million - $19.2 Million
334,840 New
334,840 $14.8 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $643M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.